Sabby Management’s Neurocrine Biosciences NBIX Stock Holding History

Sabby Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-241	Closed	-$1.36M	–	335
2015 Q4	$1.36M	Sell	241 -1,026	-81%	-$52.1K	0.08%	159
2015 Q3	$4.4M	Buy	1,267 +1,026	+426%	+$49.6K	0.18%	95
2015 Q2	$1.15M	Hold	241	–	–	0.04%	212
2015 Q1	$957K	Sell	241 -1,373	-85%	-$49.1K	0.04%	195
2014 Q4	$3.61K	Buy	1,614 +300	+23%	+$5.68K	0.11%	85
2014 Q3	$2.06K	Buy	1,314 +1,214	+1,214%	+$18.1K	0.08%	106
2014 Q2	$148K	Hold	100	–	–	0.01%	233
2014 Q1	$161K	Buy	+100	New	+$1.71K	0.01%	211
2013 Q3	–	Sell	-1,055	Closed	-$1.41M	–	215
2013 Q2	$1.41M	Buy	+1,055	New	+$13K	0.09%	104

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's NBIX Position: Q2 2016 in Review

Sabby Management sold out of Neurocrine Biosciences (NBIX) in Q2 2016, closing a stake of 70,000 shares — an estimated $3.22M sold.

Sabby Management first reported a position in NBIX in Q3 2013 and held it in 2 quarters. The position peaked at $2.77M in Q1 2016. 231 funds tracked by Wall St. Rank hold NBIX as of Q2 2016.

Sabby Management reported no remaining Neurocrine Biosciences position as of Q2 2016 after selling out during the quarter.
Sabby Management sold 70,000 Neurocrine Biosciences shares in Q2 2016, an estimated $3.22M.
Sabby Management first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 2 quarters.
Sabby Management's Neurocrine Biosciences position peaked at $2.77M in Q1 2016.
231 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.